Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer

Author:

Kok Marleen1ORCID,Gielen Robbert-Jan1,Adams Sylvia23,Lennerz Jochen K.4,Sharma Priyanka5,Loibl Sibylle67,Reardon Erin8,Sonke Gabe9,Linn Sabine1011,Delaloge Suzette12,Lacombe Denis13,Robinson Tim14,Badve Sunil15,Martin Miguel16,Balko Justin M.17,Ignatiadis Michail18,Curigliano Giuseppe1920,Wolff Antonio C.21,Mittendorf Elizabeth A.222324,Loi Sherene2526,Pusztai Lajos27,Tolaney Sara M.28,Salgado Roberto2930

Affiliation:

1. Departments of Medical Oncology and Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands

2. Perlmutter Cancer Center, NYU Langone Health, New York, NY

3. Department of Medicine, NYU Grossman School of Medicine, Manhattan, NY

4. BostonGene, Waltham, MA

5. University of Kansas Medical Center, Westwood, KS

6. GBG Forschungs GmbH, Neu-Isenburg, Germany

7. Centre for Haematology and Oncology, Bethanien, and Goethe University, Frankfurt, Germany

8. Physician, Patient

9. Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands

10. Departments of Medical Oncology and Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands

11. Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands

12. Department of Cancer Medicine, Gustave Roussy, Villejuif, France

13. European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium

14. Bristol Medical School, University of Bristol, Bristol, United Kingdom

15. Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Emory University Winship Cancer Institute, Atlanta, GA

16. Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERONC, GEICAM, Madrid, Spain

17. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

18. Breast Medical Oncology Clinic, Institut Jules Bordet, Universite Libre de Bruxelles, Bruxelles, Belgium

19. European Institute of Oncology, IRCCS, Milan, Italy

20. Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy

21. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

22. Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA

23. Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA

24. Harvard Medical School, Boston, MA

25. Division of Cancer Research, Peter MacCallum Cancer Centre, Parkville, VIC, Australia

26. The Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, VIC, Australia

27. Department of Medicine, Yale Cancer Center, Yale University, New Haven, CT

28. Dana-Farber Cancer Institute, Boston, MA

29. Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium

30. Division of Research, PeterMacCallum Cancer Centre, Melbourne, VIC, Australia

Publisher

American Society of Clinical Oncology (ASCO)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3